BioTelemetry (NASDAQ: BEAT) reported Q3 EPS of $0.16, $0.09 worse than the analyst estimate of $0.25. Revenue for the quarter came in at $81 million versus the consensus estimate of $82.62 million.

For earnings history and earnings-related data on BioTelemetry (BEAT) click here.